TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19410948

Group type: EXPERIMENTAL
Intervention: Acrylic foldable aspherical IOL (Tecnis ZA9003)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Acrylic foldable spherical IOL (AR40e)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Acrylic foldable aspherical IOL (Tecnis ZA9003) and Acrylic foldable spherical IOL (AR40e)
Number of subjects: 41
Study: 17884351

Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract containing Delta(9)‐THC and cannabidiol (CBD)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Delta(9)‐THC
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 22
Study: 15198448

Group type: EXPERIMENTAL
Intervention: Severely disabled cohort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benign cohort
Number of subjects: 0
Study: 12371348

Group type: EXPERIMENTAL
Intervention: Lidcombe Program for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (natural recovery)
Number of subjects: 23
Study: 11783270

Group type: EXPERIMENTAL
Intervention: Tongbu No. 1 (TB1)
Number of subjects: 56
Study: 7751487

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study: 2125864

Group type: EXPERIMENTAL
Intervention: Electric acupuncture stimulation (Hegu and Neiguan)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Superficial cervical plexus block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electric acupuncture stimulation (Hegu and Neiguan) with intravenous Pethedine (1.3 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 5% Glucose during operation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study: 6772889

Group type: EXPERIMENTAL
Intervention: Adult day care services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing Medicare services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adult day care services + Existing Medicare services
Number of subjects: 0
Study: 30670438

Group type: EXPERIMENTAL
Intervention: Rifapentine 1,200 mg once weekly
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg twice weekly
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Rifapentine 450 mg daily
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg daily
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Patients carrying the AA variant of AADAC rs1803155
Number of subjects: 326
Study: 27348211

Group type: EXPERIMENTAL
Intervention: Stimulant + Risperidone
Number of subjects: 165

Group type: COMPARATOR
Intervention: Stimulant + Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Stimulant only (baseline)
Number of subjects: 165
Study: 26162826

Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Sonothrombolysis (CEST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham CEST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine Alteplase with CEST
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine Alteplase with Sham CEST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Sonolysis (CES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham CES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Favourable functional outcome defined as mRS 0-1 at 90 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 24295876

Group type: EXPERIMENTAL
Intervention: Negative affect (NA)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Opioid craving
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 82
Study: 22880718

Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 257
Study: 20817132

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 17991656

Group type: EXPERIMENTAL
Intervention: GOS/lcFOS supplementation (3 times/d with 3 g GOS/lcFOS at a ratio of 9:1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GOS/lcFOS supplementation
Number of subjects: 48
Study: 16302558

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: White petrolatum (negative control)
Number of subjects: 33
Study: 11948033

Group type: EXPERIMENTAL
Intervention: Formoterol (12 or 24 microg)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Formoterol and THEO
Number of subjects: 854

Group type: COMPARATOR
Intervention: THEO
Number of subjects: 854

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 854
Study: 9794281

Group type: EXPERIMENTAL
Intervention: Pulmonary tuberculosis patients (n=53)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Long-stay orthopedic patients with lower limb fractures (n=20)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Apparently healthy controls (n=20)
Number of subjects: 53
Study: 8541696

Group type: EXPERIMENTAL
Intervention: MCT-LCT (75% medium-chain triglyceride and 25% long-chain triglyceride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: LCT (100% long-chain triglyceride)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MCT-LCT
Number of subjects: 10
Study: 2241001

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 113810

Group type: EXPERIMENTAL
Intervention: Placebo treatment for 1 week
Number of subjects: 241

Group type: COMPARATOR
Intervention: No medication (quasi-control)
Number of subjects: 241
Study: 31004676

Group type: EXPERIMENTAL
Intervention: Albiglutide liquid formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Albiglutide lyophilized formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Albiglutide liquid formulation
Number of subjects: 308

Group type: COMPARATOR
Intervention: Albiglutide lyophilized formulation
Number of subjects: 308
Study: 26670990

Group type: EXPERIMENTAL
Intervention: Ballistic exercise (10 rapid jump squats at 20% 1RM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heavy exercise (5 heavy back squats at 80% 1RM)
Number of subjects: 14
Study: 25029908

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy for 2 years after immunochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0
Study: 23438262

Group type: EXPERIMENTAL
Intervention: 60 mL/kg 0.9% saline bolus
Number of subjects: 224

Group type: COMPARATOR
Intervention: 20 mL/kg 0.9% saline bolus
Number of subjects: 224
Study: 21425571

Group type: EXPERIMENTAL
Intervention: Ligustrazine (2 mg/kg, intravenous dripping 30 min before auto-blood collection)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no ligustrazine)
Number of subjects: 40
Study: 19436018

Group type: EXPERIMENTAL
Intervention: Aspirin (alone or with dipyridamole)
Number of subjects: 5269

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 5269

Group type: EXPERIMENTAL
Intervention: Aspirin (alone)
Number of subjects: 5269
Study: 18005935

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure with Imagery Rescripting (IE+IR)
Number of subjects: 67
Study: 16972701

Group type: EXPERIMENTAL
Intervention: Adaptive design methodology
Number of subjects: 0
Study: 12904684

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 162

Group type: COMPARATOR
Intervention: Captopril (ACE inhibitor)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Amlodipine (calcium channel blocker)
Number of subjects: 162
Study: 11033188

Group type: EXPERIMENTAL
Intervention: 100% oxygen (O(2))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5% carbogen (95% O(2), 5% CO(2))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2.5% carbogen (97.5% O(2), 2.5% CO(2))
Number of subjects: 25
Study: 8872690

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg (Group LID)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg (Group E1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg (Group E2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg and Esmolol 1 mg/kg (Group LID-E1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg and Esmolol 2 mg/kg (Group LID-E2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline as a placebo (Group PLAC)
Number of subjects: 90
Study: 1504110

Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine orally
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Alprazolam treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 27
Study: 6096626

Group type: EXPERIMENTAL
Intervention: Etomidate (0.26 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 29
Study: 30942030

Group type: EXPERIMENTAL
Intervention: Moxibustion at Zusanli (ST 36), once a day for 12 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine symptomatic scheme (Control group)
Number of subjects: 60
Study: 29074099

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide (60 mg intramuscularly every 28 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg orally once daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of long-acting pasireotide and everolimus
Number of subjects: 124
Study: 26136351

Group type: COMPARATOR
Intervention: 20mg methylphenidate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Premature responses after prior feedback
Number of subjects: 28
Study: 23218662

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided surgery
Number of subjects: 134

Group type: COMPARATOR
Intervention: Palpation-guided surgery
Number of subjects: 134
Study: 21695666

Group type: EXPERIMENTAL
Intervention: Moderate endurance training (n=7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Strength training (n=7)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 21
Study: 18496950

Group type: EXPERIMENTAL
Intervention: Less invasive technique for EC-IC bypass
Number of subjects: 39
Study: 16643262

Group type: EXPERIMENTAL
Intervention: BASO II trial (treatment trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBIS (prevention trial)
Number of subjects: 0
Study: 15260877

Group type: EXPERIMENTAL
Intervention: General movement experience
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Task-related movement experience
Number of subjects: 30

Group type: COMPARATOR
Intervention: No movement experience
Number of subjects: 30
Study: 11418256

Group type: EXPERIMENTAL
Intervention: Paid and unpaid television and print‐media advertising, physician mail‐outs, and community‐level support programs and strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison region (other states of Australia)
Number of subjects: 0
Study: 9269694

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 93
Study: 8277144

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 3828958

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 27820972

Group type: EXPERIMENTAL
Intervention: CL-GVS (cathode on the left mastoid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CR-GVS (cathode on the right mastoid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham-GVS
Number of subjects: 24
Study: 26685849

Group type: EXPERIMENTAL
Intervention: Azithromycin for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amoxicillin/metronidazole for 7 days
Number of subjects: 60
Study: 24158845

Group type: EXPERIMENTAL
Intervention: First-eye phacoemulsification surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Second-eye phacoemulsification surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: UV-blocking or blue-blocking IOL
Number of subjects: 80
Study: 23747646

Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (6 times per week, twice daily for 10-20 minutes, for 6 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Home-based treadmill training
Number of subjects: 12
Study: 20032102

Group type: EXPERIMENTAL
Intervention: rAAV2‐TNFR:Fc (1 x 10(11), 1 x 10(12), or 1 x 10(13) DNase‐resistant particles/ml joint volume)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 19044302

Group type: EXPERIMENTAL
Intervention: Permixon
Number of subjects: 3

Group type: COMPARATOR
Intervention: tamsulosin
Number of subjects: 3
Study: 16683146

Group type: EXPERIMENTAL
Intervention: Hypofractionated preoperative radiotherapy (5x5 Gy)
Number of subjects: 148

Group type: COMPARATOR
Intervention: TME/PME surgery alone
Number of subjects: 148
Study: 14529892

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 60
Study: 10759886

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with continuous intravenous infusion of antithrombin III and two intraperitoneal instillations of fresh frozen human donor serum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with antithrombin III and serum
Number of subjects: 50
Study: 8989857

Group type: EXPERIMENTAL
Intervention: Using a picture as an organizing cue for the second passage just before retrieval of the first passage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 1639655

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy followed by local treatment and maintenance therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Radiation only to the intact breast and regional nodes
Number of subjects: 107

Group type: COMPARATOR
Intervention: Mastectomy followed by postoperative radiotherapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 107
Study: 6712858

Group type: EXPERIMENTAL
Intervention: prizidilol (n = 10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: propranolol (n = 12)
Number of subjects: 22
Study: 31369607

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study: 30170898

Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 69
Study: 26862008

Group type: EXPERIMENTAL
Intervention: Six meals per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three meals per day
Number of subjects: 40
Study: 24246820

Group type: EXPERIMENTAL
Intervention: 6-month, gender-tailored SHED-IT Weight Loss Maintenance Program (n = 47)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Self-help control group (n = 45)
Number of subjects: 92
Study: 23291020

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: UDCA and prednisolone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: UDCA and azathioprine
Number of subjects: 79
Study: 20653294

Group type: EXPERIMENTAL
Intervention: HeartMath self‐regulation skills and coherence training program
Number of subjects: 38
Study: 19047976

Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg q.i.d., amoxicilline 1 gr b.i.d. and PPI standard dose (MAO)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Tinidazole 500 mg b.i.d., amoxicilline 1 gr b.i.d. and PPI standard dose (TAO)
Number of subjects: 171
Study: 16077882

Group type: EXPERIMENTAL
Intervention: Endovascular management of AAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 0
Study: 12877415

Group type: EXPERIMENTAL
Intervention: Bonded resin composite restoration with cuspal coverage
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bonded resin composite restoration without cuspal coverage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the absence of cuspal coverage)
Number of subjects: 40
Study: 11107885

Group type: EXPERIMENTAL
Intervention: Psychotherapy efficacy studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy effectiveness studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technique-focused research
Number of subjects: 0
Study: 8756037

Group type: COMPARATOR
Intervention: Temporal(R)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Taver(R)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Carbamazepine Lincoln
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tegretol(R)
Number of subjects: 7
Study: 1533022

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 42
Study: 2865120

Group type: EXPERIMENTAL
Intervention: Metronidazole monotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination of cortisone, salazosulfapyridine and metronidazole
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cortisone and salazosulfapyridine
Number of subjects: 52
Study: 29275068

Group type: EXPERIMENTAL
Intervention: Sucrose octasulfate dressing
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control dressing
Number of subjects: 240
Study: 27432821

Group type: EXPERIMENTAL
Intervention: L-carnitine (990 mg twice daily) for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 24393346

Group type: EXPERIMENTAL
Intervention: Behaviour and chronotherapy intervention (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Behaviour intervention only (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 22433400

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 20228983

Group type: EXPERIMENTAL
Intervention: Ketoconazole tablet (200 mg per day for 14 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical ketoconazole 2% in orabase (applied twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between ketoconazole tablet and topical ketoconazole
Number of subjects: 30
Study: 18334581

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 39
Study: 16518989

Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional blunt dissection tonsillectomy
Number of subjects: 0
Study: 12785457

Group type: EXPERIMENTAL
Intervention: Tramadol 75 mg plus acetaminophen 650 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen combination
Number of subjects: 0
Study: 11872340

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (RT) at 20 Gray (Gy)/5 fractions
Number of subjects: 75
Study: 9527091

Group type: EXPERIMENTAL
Intervention: Soluble vascular cell adhesion molecule-1 (VCAM-1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E-selectin
Number of subjects: 23
Study: 8703648

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methoxamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Local infusions and/or systemic treatments
Number of subjects: 8
Study: 2088631

Group type: EXPERIMENTAL
Intervention: Fluroshield sealant (2% NaF, 1% adhesion promoter)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prisma-Shield sealant (non-fluoride containing)
Number of subjects: 82
Study: 370109

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (150 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Diazepam (20 mg daily)
Number of subjects: 53
Study: 6306060

Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30001469

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (0, 400, 1000, 2000, or 4000 IU/d for 12 weeks)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 324
Study: 26894422

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (basal condition)
Number of subjects: 0
Study: 25521843

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 22360623

Group type: EXPERIMENTAL
Intervention: Random-SOA arrangements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant-SOA arrangements
Number of subjects: 0
Study: 21029813

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1659
Study: 18547294

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg.kg(‐1))
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 15929962

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 78
Study: 12678150

Group type: EXPERIMENTAL
Intervention: Xylocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 70
Study: 10648337

Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60